Clinical application of magnesium isoglycyrrhizinate_Kain Industrial Additives

Overview^[1]

Magnesium isoglycyrrhizinate is an organic metal compound that can be used for chronic viral hepatitis to improve liver function abnormalities. Magnesium isoglycyrrhizinate is a liver cell protective agent that has the effects of anti-inflammation, protecting liver cell membranes and improving liver function. Magnesium isoglycyrrhizinate has a preventive and therapeutic effect on acute liver injury in rats caused by D-galactosamine. It can prevent the increase in animal serum aminotransferases and reduce liver cell degeneration, necrosis and inflammatory cell infiltration. It has a therapeutic effect on chronic liver injury and reduces the inflammatory activity of liver tissue. and degree of fibrosis.

Clinical application^[2]

1. Treatment of acute and chronic hepatitis

Using magnesium isoglycyrrhizinate to treat chronic hepatitis B virus, the total effective rate is 88.37%. The patient’s symptoms, signs, liver function and liver fibrosis indicators were significantly improved (P0.05), and no serious adverse reactions occurred, indicating that magnesium isoglycyrrhizinate is safe and effective in the treatment of chronic hepatitis B virus. It has also been reported that the total effective rate of magnesium isoglycyrrhizinate in treating viral hepatitis is 96.3% [15], and the effective rate in treating chronic severe hepatitis is 73.3%. It is better than hepatocyte growth hormone in improving liver function indicators and promoting liver cell regeneration. And no adverse reactions occurred. In addition, magnesium isoglycyrrhizinate combined with Xuesaitong can significantly improve liver function and blood lipid indicators in patients with non-alcoholic steatohepatitis.

2. Treatment of drug-induced liver damage

In a clinical efficacy study, it was found that magnesium isoglycyrrhizinate can significantly improve the clinical symptoms and liver function indicators of drug-induced liver damage, and the recovery time of glutamate aminotransferase (ALT) to normal is short and fast. , less adverse reactions. In another clinical observation, the effective rate of magnesium isoglycyrrhizinate in treating acute drug-induced liver injury was 76.5%, and the total effective rate was 94.1%.

3. Treatment of nephrotic syndrome

Hemorrhagic fever nephrotic syndrome Hemorrhagic fever is a syndrome characterized by extensive damage to small blood vessels and capillaries throughout the body as the main pathological change.

Magnesium isoglycyrrhizinate injection is used to treat hemorrhagic fever with nephrotic syndrome. The treatment group is significantly better than the control group in terms of platelet recovery time, liver and kidney function recovery time, exudation and congestion time, and urine protein disappearance time. There is a significant difference after statistical processing. It shows that magnesium isoglycyrrhizinate injection is effective in treating hemorrhagic fever with nephrotic syndrome and has few side effects, which may be related to its multiple effects such as inducing endogenous interferon, inhibiting virus replication, and promoting the repair of kidney damage.

4. In transcatheter arterial chemoembolization (TACE)

The liver-protective effect of TACE in the treatment of liver cancer is the first choice for the treatment of intermediate and advanced liver cancer. However, most liver cancer patients in my country have underlying diseases of cirrhosis and varying degrees of liver insufficiency. TACE can aggravate liver function damage and even lead to liver failure, thus affecting the clinical effect of TACE. Studies have shown that magnesium isoglycyrrhizinate given immediately after TACE treatment can antagonize the side effects of TACE. The incidence of post-chemoembolization syndrome, edema, and peritoneal effusion in the treatment group was significantly lower than that of the control group, and the cytopenias were significantly better than those in the control group.

5. Improve the immune regulatory function of regulatory T cells

Primary biliary cirrhosis (PBC) is an autoimmune liver disease characterized by chronic non-suppurative granulomatous cholangitis in the intrahepatic bile ducts. Patients have immune dysfunction, intrahepatic and peripheral There was a significant decrease in regulatory T cells in the blood, and they play an important role in maintaining immune tolerance. Hospitalized PBC patients without hormone therapy were randomly divided into magnesium isoglycyrrhizinate treatment group and ursodeoxycholic acid control group. After 4 weeks of treatment, all indicators of liver function in the treatment group were significantly improved, and there was a significant difference compared with the control group. At the same time, The proportion of regulatory T cells in the peripheral blood of the treatment group increased significantly after treatment, while there was no significant change in the control group. It is speculated that magnesium isoglycyrrhizinate may inhibit the damage of autoreactive T cells to cholangiocytes and liver by improving the immune regulatory function of regulatory T cells.

Pharmacokinetic characteristics^[3]

In order to explore the pharmacokinetic characteristics of magnesium isoglycyrrhizinate injection in the human body, 9 healthy volunteers were given a single dose of intravenous infusion of three different doses (100, 200, 300 mg) of magnesium isoglycyrrhizinate injection. Venous blood was taken at the designed time points, and the plasma drug concentration was measured using high-performance liquid chromatography-ultraviolet detection.

The results showed that the in vivo process of healthy volunteers after intravenous infusion of magnesium isoglycyrrhizinate injection showed linear characteristics, and the blood concentration-time data conformed to the two-compartment model of first-order elimination, which is consistent with the research of Shen Jinfang et al. The results are consistent, suggesting that magnesium isoglycyrrhizinate has a slower elimination rate than glycyrrhizic acid and other glycyrrhizinate drugs, which is beneficial to the treatment of chronic hepatitis. In order to evaluate the safety and tolerability of magnesium isoglycyrrhizinate injection in healthy volunteers, the effects of single intravenous infusion of 100 mg, 200 mg, 300 mg of magnesium isoglycyrrhizinate injection and continuous administration of 200 mg once a day for 7 days were observed. Results Immediately after a single administration and 1, 8, and 24 hours after administration, no abnormal changes were found in the subjects’ vital signs and laboratory indicators compared with those before administration. On the 4th and 8th days after continuous administration, The subjects’ vital signs and laboratory indicators were within normal limits. It shows that normal human body has good tolerance to magnesium isoglycyrrhizinate injection, and the recommended daily dose is 100~200mg.